Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia.

Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, Graziosi C, Schnittman SS, Quinn TC, Shaw GM, Perrin L, Tambussi G, Lazzarin A, Sekaly RP, Soudeyns H, Corey L, Fauci AS.

Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):254-8.

2.

CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression.

Malhotra U, Huntsberry C, Holte S, Lee J, Corey L, McElrath MJ.

Clin Immunol. 2006 Apr;119(1):95-102. Epub 2006 Jan 5.

PMID:
16403675
3.

Immunopathogenesis of HIV infection.

Pantaleo G, Fauci AS.

Annu Rev Microbiol. 1996;50:825-54. Review.

PMID:
8905100
4.

Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia.

Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, Hagos E, Nixon DF, Deeks SG.

AIDS. 2004 Apr 30;18(7):981-9.

PMID:
15096800
5.

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.

Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, Montefiori D, Orenstein JM, Fox C, Schrager LK, et al.

N Engl J Med. 1995 Jan 26;332(4):209-16.

6.

Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.

Petrara MR, Cattelan AM, Zanchetta M, Sasset L, Freguja R, Gianesin K, Cecchetto MG, Carmona F, De Rossi A.

J Clin Virol. 2012 Mar;53(3):195-200. doi: 10.1016/j.jcv.2011.12.013. Epub 2011 Dec 30.

PMID:
22209290
7.

Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia.

Pasternak AO, Jurriaans S, Bakker M, Berkhout B, Lukashov VV.

AIDS. 2010 Jul 17;24(11):1641-9. doi: 10.1097/QAD.0b013e32833b3171.

PMID:
20543660
8.

Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, Clarke JR, Johnson GE, Weber JN, Phillips RE.

J Virol. 2003 May;77(10):6041-9.

9.
10.

Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection.

Henrard DR, Daar E, Farzadegan H, Clark SJ, Phillips J, Shaw GM, Busch MP.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jul 1;9(3):305-10.

PMID:
7788430
11.

Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS.

Blattner WA, Oursler KA, Cleghorn F, Charurat M, Sill A, Bartholomew C, Jack N, O'Brien T, Edwards J, Tomaras G, Weinhold K, Greenberg M.

J Infect Dis. 2004 May 15;189(10):1793-801. Epub 2004 Apr 26.

12.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

13.
14.

The independent effect of drug resistance on T cell activation in HIV infection.

Hunt PW, Deeks SG, Bangsberg DR, Moss A, Sinclair E, Liegler T, Bates M, Tsao G, Lampiris H, Hoh R, Martin JN.

AIDS. 2006 Mar 21;20(5):691-9.

PMID:
16514299
15.

No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.

Brumme ZL, Chan KJ, Dong WW, Mo T, Wynhoven B, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR.

AIDS. 2002 Sep 27;16(14):1929-33.

PMID:
12351953
16.

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC.

Ann Intern Med. 1996 Jun 15;124(12):1039-50.

PMID:
8633817
17.

Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline.

Iuliano R, Forastieri G, Brizzi M, Mecocci L, Mazzotta F, Ceccherini-Nelli L.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):408-14.

PMID:
9170414
18.

Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection.

Graziosi C, Pantaleo G, Butini L, Demarest JF, Saag MS, Shaw GM, Fauci AS.

Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6405-9.

19.

Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years.

Arnó A, Ruiz L, Juan M, Zayat MK, Puig T, Balagué M, Romeu J, Pujol R, O'Brien WA, Clotet B.

AIDS. 1998 May 7;12(7):697-704.

PMID:
9619800
20.

Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.

Zaunders JJ, Cunningham PH, Kelleher AD, Kaufmann GR, Jaramillo AB, Wright R, Smith D, Grey P, Vizzard J, Carr A, Cooper DA.

J Infect Dis. 1999 Aug;180(2):320-9.

Items per page

Supplemental Content

Write to the Help Desk